Compounds > 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
Page last updated: 2024-10-21

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and MPTP Neurotoxicity Syndrome

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with MPTP Neurotoxicity Syndrome in 1 studies

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lange, KW1
Löschmann, PA1
Sofic, E1
Burg, M1
Horowski, R1
Kalveram, KT1
Wachtel, H1
Riederer, P1

Other Studies

1 other study available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and MPTP Neurotoxicity Syndrome

ArticleYear
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates.
    Naunyn-Schmiedeberg's archives of pharmacology, 1993, Volume: 348, Issue:6

    Topics: Animals; Behavior, Animal; Biogenic Monoamines; Callithrix; Female; Immunohistochemistry; Male; MPTP

1993